Sort
48,018 grants matching “immunotherapy”
Overcoming stromal barriers to therapeutics in pancreas cancer
$525,536Sunil R Hingorani · Fred Hutchinson Cancer Research Center · R01 · FY2016 · CA
Modulation of the tumor microenvironment with probiotic therapies
$525,502Tal Danino · Columbia Univ New York Morningside · R01 · FY2024 · CA
Laboratory and Clinical studies on T-cells recognizing Non-Small Cell Lung Cancer
$525,487James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Characterization of Pigmentary Disorders and Melanoma Targeting
$525,446Vincent J Hearing · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Next-generation genetic engineering of the pan-leukocyte antigen CD45 to facilitate CAR-T cell therapy against hematologic malignancies
$525,419Saar Gill · University Of Pennsylvania · P01 · FY2025 · CA
Role of autophagy-related protein Vps34 in antigen presentation and self-tolerance
$525,370Luc Van Kaer · Vanderbilt University Medical Center · R01 · FY2021 · AI
Role of autophagy-related protein Vps34 in antigen presentation and self-tolerance
$525,370Luc Van Kaer · Vanderbilt University Medical Center · R01 · FY2019 · AI
Role of autophagy-related protein Vps34 in antigen presentation and self-tolerance
$525,370Luc Van Kaer · Vanderbilt University Medical Center · R01 · FY2020 · AI
Role of autophagy-related protein Vps34 in antigen presentation and self-tolerance
$525,370Luc Van Kaer · Vanderbilt University Medical Center · R01 · FY2023 · AI
Novel strategies to improve mesothelioma therapy
$525,368Haining Yang · University Of Hawaii At Manoa · R01 · FY2025 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation
$525,246Benjamin G Vincent · Univ Of North Carolina Chapel Hill · R37 · FY2022 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation
$525,246Benjamin G Vincent · Univ Of North Carolina Chapel Hill · R37 · FY2020 · CA
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation
$525,246Benjamin G Vincent · Univ Of North Carolina Chapel Hill · R37 · FY2021 · CA
Developing clinically relevant PET tracers to image T cell activation for improved cancer immunotherapy monitoring
$525,196Michelle Louise James · Stanford University · R01 · FY2024 · CA
Project 1: Evaluating the synergy of LAG3 and PD-1 in melanoma patients
$525,166Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · P50 · FY2025 · CA
Flexible NLP toolkit for automatic curation of outcomes for breast cancer patients
$525,159Imon Banerjee · Mayo Clinic Arizona · U01 · FY2022 · CA
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
$525,122Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy
$525,103Robert M. Waymouth · Stanford University · R01 · FY2024 · CA
Structural Basis of Murine Diabetes
$525,089Luc Teyton · Scripps Research Institute, The · R01 · FY2007 · DK
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment
$525,061Jianjun Gao · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Adaptive-Innate Immune Crosstalk in TGF-B Control of Peripheral T Cell Tolerance
$525,032Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2016 · AI
SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma
$525,001Anthony Charles Faber · Virginia Commonwealth University · R01 · FY2024 · CA
ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
$525,000Scripps Research Institute · R01 · FY2000 · HL
Identifying Therapeutic Targets for Stage III Melanoma
$524,991Anand K Ganesan · University Of California-Irvine · R01 · FY2023 · CA
Immune Dysregulation by Human Papillomavirus during Head and Neck Cancer Progression
$524,976Dohun Pyeon · University Of Colorado Denver · R01 · FY2017 · DE